OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech, a Ghana-based genomics company building the world’s most diverse cancer bio-database to develop next-generation cancer drugs that work across diverse populations.
Yemaachi Biotech‘s work is rooted in a simple but powerful conviction: precision oncology research, diagnostics, and therapeutics must be inclusive to be truly effective, and that the data gap in African genomics is not just a scientific problem, but a human one.
This investment reflects OneBio’s continued commitment to backing founders who are solving problems that matter globally, starting from Africa.
Source: OneBio Venture Studio